PLYX · Polaryx Therapeutics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These matters, along with the conditions described above, raise substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the date these financial statements were available to be issued.”View the 10-Q filed May 15, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-05-27 | Yang Alex Keun Mo |
Director, Chief Executive Officer, 10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
As disclosed in the Issuer's Form 8-K filed with the Securities and Exchange Commission on May 28, 2026, MStone Partners Healthcare Limited ("Mstone") purchased 88,453 shares of common stock in a private placement transaction, for gross proceeds to the Issuer of $360,000. Alex Keun Mo Yang is the founder and Chief Executive Officer of Mstone. Mr. Yang disclaims beneficial ownership over any of the reported securities, except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
88,453 |
| 2026-02-18 | Landis G. Michael |
Director, Chief Financial Officer |
Buy↑
|
Common Stock
|
2,867 |
| 2026-01-29 | Ryan Charles S. |
President |
Other↑
|
No Securities Owned
|
0 |
| 2026-01-29 | Braun III Francis A |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2026-01-29 | Berger Mitchel |
Director |
Other↑
|
No Securities Owned
|
0 |